Last reviewed · How we verify
Baclofen IR
Baclofen IR is a central nervous system depressant that acts as a GABA_B receptor agonist.
Baclofen IR is a central nervous system depressant that acts as a GABA_B receptor agonist. Used for Spasticity associated with multiple sclerosis, Spasticity associated with spinal cord injuries.
At a glance
| Generic name | Baclofen IR |
|---|---|
| Also known as | CAS Registry Number [11134-47-0] |
| Sponsor | Impax Laboratories, LLC |
| Drug class | GABA receptor agonist |
| Target | GABA_B receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Baclofen IR works by activating GABA_B receptors in the central nervous system, which leads to a decrease in muscle tone and spasticity. This results in relief from symptoms associated with conditions such as multiple sclerosis and spinal cord injuries.
Approved indications
- Spasticity associated with multiple sclerosis
- Spasticity associated with spinal cord injuries
Common side effects
- Drowsiness
- Dizziness
- Nausea
- Headache
Key clinical trials
- A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis (PHASE2)
- ALK29-002: A Study of Baclofen Formulations in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baclofen IR CI brief — competitive landscape report
- Baclofen IR updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI